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Corona virus disease 2019 (COVID-19) is an infectious 
disease caused by severe acute respiratory syndrome 
corona virus 2 (SARS-CoV-2).[1] It was first identified in 
December 2019 in Wuhan, Hubei, China, and has 
resulted in an ongoing pandemic.[2,3] As of 13 August 
2020, more than 20.6 million cases have been 
reported    across    188    countries     and    territories,  
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resulting in more than 749,000 deaths. More than 
12.8 million people have recovered.[4,5] There are 
approximately 17 million cases and more than 6 lakhs 
deaths have been reported globally till August 1, 2020 
by WHO. In India, the figure has risen to about 16 
lakhs of total cases and 36,511 cases have deceased 
during fighting with the disease. In India, the 
prevalence rate is more in places with crowded areas 
like Delhi and certain cities of Maharashtra, 
Tamilnadu.[6] 
Corona viruses are a family of viruses that can cause 
illnesses such as the common cold, severe acute 
respiratory syndrome (SARS) and Middle East 
respiratory syndrome (MERS). In 2019, a new corona 
virus was identified as the cause of a disease outbreak 
that originated in China. The virus is now known as 
the severe acute respiratory syndrome corona virus 2 
(SARS-CoV-2). The disease it causes is called corona 
virus disease 2019 (COVID-19). Signs and symptoms of 
corona virus disease 2019 (COVID-19) may appear two 
to 14 days after exposure. This time after exposure 
A B S T R A C T  
Viral diseases are one of the major causes of devastation in human history world wide. Bacterial and 
parasitic diseases can be controlled by the use of effective antibodies and anti-parasitic agents 
respectively. Since viruses do replicate inside the cells and any intervention will affect the cellular 
metabolism of the host. Development of antiviral drug is a challenge. COVID-19 is the infectious 
disease caused by the most recently discovered corona virus. This new virus and disease were 
unknown before the outbreak began in Wuhan, China, in December 2019. COVID -19 is declared as a 
pandemic by WHO in the month of March. No cure has yet been found for the disease; however, 
nowadays it is being managed through symptomatic treatment by using corticosteroids and antibiotics 
to prevent or subside bacterial infections. As all infected people do not develop severe disease and 
even most of them are having either mild symptoms or symptoms less. From the recent data we 
found that most of the patients who developed severe symptoms have already had some chronic 
ailments like diabetes, HTN and were already in an immune-compromised state. So, through 
Ayurvedic approach we can try to boost up immunity of the patient and hence can  reduce the 
mortality rate and burden of providing health facilities  in our country.  
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and before having symptoms is called the incubation 
period. Common signs and symptoms can include 
fever, cough and tiredness. Early symptoms of COVID-
19 may include a loss of taste or smell. Other 
symptoms can include shortness of breath or difficulty 
in breathing, muscle aches, chill, sore throat, runny 
nose, headache, chest pain.[7] 
Pathophysiology 
Corona viruses are enveloped, positive-sense, single-
stranded RNA viruses of ~30 kb. They infect a wide 
variety of hostspecies.[8] They are largely divided into 
four genera; α, β, γ, and δ based on their genomic 
structure. α and β coronaviruses infect only mammals.  
In contrast, SARS-CoV, Middle East respiratory 
syndrome corona virus (MERS-CoV) and SARS-CoV-2 
are classified to β corona viruses.[9] 
The life cycle of the virus with the host consists of the 
following 5 steps: attachment, penetration, 
biosynthesis, maturation and release. Once viruses 
bind to host receptors (attachment), they enter host 
cells through endocytosis or membrane fusion 
(penetration). Once viral contents are released inside 
the host cells, viral RNA enters the nucleus for 
replication. Viral mRNA is used to make viral proteins 
(biosynthesis). Then, new viral particles are made 
(maturation) and released. Corona viruses consist of 
four structural proteins; Spike (S), membrane (M), 
envelop (E) and nucleocapsid (N).[10] Spike is 
composed of a transmembrane trimetric glycoprotein 
protruding from the viral surface, which determines 
the diversity of corona viruses and host tropism. Spike 
comprises two functional subunits; S1 subunit is 
responsible for binding to the host cell receptor and 
S2 subunit is for the fusion of the viral and cellular 
membranes. Angiotensin converting enzyme 2 (ACE2) 
was identified as a functional receptor for SARS-
CoV.[11] ACE2 expression was high in lung, heart, 
ileum, kidney and bladder.[12] In the lung, ACE2 was 
highly expressed on lung epithelial cells. Whether or 
not SARS-CoV-2 binds to an additional target needs 
further investigation. Following the binding of SARS-
CoV-2 to the host protein, the spike protein 
undergoes protease cleavage. After the cleavage at 
the S1/S2 cleavage site, S1 and S2 subunits remain 
non-covalently bound and the distal S1 subunit 
contributes to the stabilization of the membrane-
anchored S2 subunit at the prefusion site. Subsequent 
cleavage at the S′2 site presumably activates the spike 
for membrane fusion via irreversible, conformational 
changes. The corona virus spike is unusual among 
viruses because a range of different proteases can 
cleave and activate it. The characteristic unique to 
SARS-CoV-2 among corona viruses is the existence of 
furin cleavage site (“RPPA” sequence) at the S1/S2 
site. The S1/S2 site of SARS-CoV-2 was entirely 
subjected to cleavage during biosynthesis in a drastic 
contrast to SARS-CoV spike, which was incorporated 
into assembly without cleavage. Although the S1/S2 
site was also subjected to cleavage by other proteases 
such as transmembrane protease serine 2 (TMPRSS2) 
and cathepsinl, the ubiquitous expression of furin 
likely makes this virus very pathogenic.[13,14,15] 
Host response to SARS-CoV-2 
The symptom of patients infected with SARS-CoV-2 
ranges from minimal symptoms to severe respiratory 
failure with multiple organ failure. On Computerized 
tomography (CT) scan, the characteristic pulmonary 
ground glass opacification can be seen even in 
asymptomatic patients.[16] Because ACE2 is highly 
expressed on the apical side of lung epithelial cells in 
the alveolar space, this virus can likely enter and 
destroy them.[17,18] This matches with the fact that the 
early lung injury was often seen in the distal airway. 
Epithelial cells, alveolar macrophages and dendritic 
cells (DCs) are three main components for innate 
immunity in the airway.[19] DCs reside underneath the 
epithelium. Macrophages are located at the apical 
side of the epithelium. DCs and macrophages serve as 
innate immune cells to fight against viruses till 
adaptive immunity is involved. T cell mediated 
responses against corona viruses have been 
previously reviewed.[20] T cell responses are initiated 
by antigen presentation via DCs and macrophages. 
How does SARS-CoV-2 enter APCs? DCs and 
macrophages can phagocytize apoptotic cells infected 
by virus.[21] For example, virus-infected apoptotic 
epithelial cells can be phagocytized by DCs and 
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macrophages, which lead to antigen presentation to T 
cells. Or DCs and macrophages may be infected with 
viruses primarily? Based on the Immunological 
Genome database (http://rstats.immgen.org), the 
expression of ACE2 on (splenic) dendritic cells and 
alveolar macrophages is present but limited. 
Determining whether or not SARS-CoV-2 uses another 
protein to bind to APCs helps to answer this question. 
SARS-CoV can also bind to dendritic-cell specific 
intercellular adhesion molecule-3-grabbing non 
integrin (DC-SIGN) and DC-SIGN-related protein (DC-
SIGNR, L-SIGN) in addition to ACE2.[22,23,24] DC-SIGN is 
highly expressed on dendritic cells and macrophages. 
Another target for SARS-CoV-2, if any, can help the 
virus to directly infect DCs and alveolar macrophages. 
This needs future research. These antigen presenting 
cells move to the draining lymph nodes to present 
viral antigens to T cells. CD4+ and CD8+ T cells play a 
critical role. CD4+ T cells activate B cells to promote 
the production of virus-specific antibody, while CD8+ 
T cells can kill viral infected cells.[25] 
Clinical Presentation 
Clinical and epidemiological data from the Chinese 
CDC and regarding 72,314 case records (confirmed, 
suspected, diagnosed, and asymptomatic cases) were 
shared in the Journal of the American Medical 
Association (JAMA), providing the first important 
illustration of the epidemiologic curve of the Chinese 
outbreak. There were 62% confirmed cases, including 
1% of cases that were asymptomatic, but were 
laboratory positive (viral nucleic acid test). Further 
more, the overall case-fatality rate (in confirmed 
cases) was 2.3%. Of note, the fatal cases were 
primarily elderly patients, in particular those aged ≥ 
80 years (about 15%) and 70 to 79 years (8.0%). 
Approximately half (49.0%) of the critical patients and 
affected by preexisting comorbidities such as 
cardiovascular disease, diabetes, chronic respiratory 
disease and oncological diseases, died. While 1% of 
patients were aged 9 years or younger, no fatal cases 
occurred in this group. The authors of the Chinese 
CDC report divided the clinical manifestations of the 
disease by their severity. 
▪ Mild disease: Non-pneumonia and mild 
pneumonia; this occurred in 81% of cases. 
▪ Severe disease: Dyspnea, respiratory frequency ≥ 
30/min, blood oxygen saturation (SpO2) ≤ 93%, 
PaO2/FiO2 ratio or P/F [the ratio between the 
blood pressure of the oxygen (partial pressure of 
oxygen, PaO2) and the percentage of oxygen 
supplied (fraction of inspired oxygen, FiO2)] < 300, 
and/or lung infiltrates > 50% within 24 to 48 
hours; this occurred in 14% of cases. 
▪ Critical disease: respiratory failure, septic shock, 
and/or multiple organ dysfunction (MOD) or 
failure (MOF); this occurred in 5% of cases.[26] 
Diagnostic criteria 
According to the seventh edition of MMR (3 March 
2020), to confirm the suspected case needs to 
combine any one item of epidemiological history 
features with two items of clinical manifestations to 
make a comprehensive analysis, or needs to meet 
three items of clinical manifestations if without clear 
epidemiological history: 
Epidemiological history 
1. A history of travel or residence in communities 
where COVID-19 cases had been reported in the 
last 14 days before symptom onset; 
2. A history of contact with SARS-CoV-2 infectious 
cases (with positive nucleic acid test); 
3. A history of contacting a cluster of confirmed 
cases (≥ 2 cases with fever and/or respiratory 
symptoms occurred within 2 weeks in small areas, 
such as home, office, class of school, etc). 
Clinical manifestations 
1. Fever and/ or respiratory symptoms; 
2. Imaging features of COVID-19infection; 
3. Total white blood cell counts showing normal or 
reduced lymphocyte count in the early onset 
stage. 
However, anyone can catch COVID-19 and become 
seriously ill.  People of all ages who experience fever 
and/or cough associated with difficulty in  
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breathing/shortness of breath, chest pain/pressure, or 
loss of speech or movement should seek medical 
attention immediately. If possible, it is recommended 
to call the health care provider or facility first, so the 
patient can be directed to the right clinic. 
Diagnosis 
Diagnosing the confirmed case should base on 
suspected case with any one item of pathogenic or 
serological evidence as following: (1) SARS-CoV-2 
nucleic acid positive in samples of sputum, pharynx 
swabs, and secretions of lower respiratory tract 
tested by real-time reverse-transcriptase–
polymerase-chain reaction (rRT-PCR) assay.; (2) viral 
whole genome sequencing showing high homogeneity 
to the known novel coronaviruses; (3) positive for the 
specific IgM antibody and IgG antibody to SARS-CoV-2 
in serum test; or a change of the SARS-CoV-2-specific 
IgG antibody from negative to positive.[27] 
The ACR believes that the following factors should be 
considered regarding the use of imaging for suspected 
or known COVID-19 infection: 
The Centers for Disease Control (CDC) does not 
currently recommend CXR or CT to diagnose COVID-
19. Viral testing remains the only specific method of 
diagnosis. Confirmation with the viral test is required, 
even if radiologic findings are suggestive of COVID-19 
on CXR or CT. For the initial diagnostic testing for 
suspected COVID-19 infection, the CDC recommends 
collecting and testing specimens from the upper 
respiratory tract (nasopharyngeal AND oropharyngeal 
swabs) or from the lower respiratory tract when 
available for viral testing. 
Generally, the findings on chest imaging in COVID-19 
are not specific, and overlap with other infections, 
including influenza, H1N1, SARS and MERS. Being in 
the midst of the current flu season with a much higher 
prevalence of influenza in the U.S. than COVID-19, 
further limits the specificity of CT.[28] 
Preventions 
Recommended measures to prevent infection include 
frequent hand washing, maintaining physical distance 
from others (especially from those with symptoms), 
quarantine (especially for those with symptoms), 
covering coughs, and keeping unwashed hands away 
from the face.[28] There are neither proven vaccines 
nor specific antiviral treatments for COVID-19. 
Management involves the treatment of symptoms, 
supportive care, isolation, and experimental 
measures.[29] 
Ayurvedic Approach 
In Ayurveda there is the term Vyadhikshmatva coined 
by Acharya Charaka in Sutrasthana 28th chapter which 
means the power of the body which decreases the 
Bala (or strength) of diseases and stops its 
progression. In modern terms it can be compared to 
immunity. Acharaya Charaka also mentioned that if a 
group of people aretaking the same uncompatible 
diet then it is not necessary that all of them get ill or if 
all people get ill then not all will die due to severity of 
disease. Some will recover.[30] This form the basis that 
there is a concept of immunity exists in Ayurveda and 
the herbs which boost up our immune system are 
called as Rasayana according to Ayurveda. There are 
three types of Bala; Sahaj, Kalaj, Yuktikrita. 
Sahajbala can be compared with the immunity with 
which the child is born. Kalajbala is depend upon the 
age of a person and the seasonal variation as old 
people get ill easily as compared to adult one and also 
a person have low immunity in summer season as 
compared to winter according to Ayurveda Whereas 
Yuktikrtabala is achieved when a person take 
wholesome diet that means a person taking balanced 
diet has good immunity as compared to the one who 
takes improper diet.[31] In many Samhita there are 
some drugs given by Acharyas to enhance Bala i.e,  
immunity. Some experimental research has been 
done on the herbs which have been used to boost up 
immunity (Bala) since ancient times mentioned in 
Ayurveda to check their potential.  In order to 
investigate mechanism of action of the Rasayana e.g. 
Tinospora cordifolia studies are carried out on the 
proliferative fraction of the bone marrow of mice by 
flow cytometry and found that compared with normal 
mice, there was a significant increase in the 
proliferative fraction in the bone marrow in mice 
treated with the Tinospora cordifolia. 
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The active principles of Guduchi (Tinospora cordifolia), 
have been found to possess anticomplementary and 
immunostimulating activities. Previous studies on the 
extracts of Guduchi reported anti-inflammatory and 
hepatoprotective activities. Syringin (TC-4) inhibited 
the in vitro immune haemolysis of antibody coated 
erythrocytes. The reduced immunohaemolysis was 
found to be due to inhibition of the C3-convertase of 
the classical complement pathway. Humoral and cell 
mediated immunity were also dose dependently 
enhanced. Macrophage activation was reported for 
cordioside (TC-2), cardiofolioside – A (TC-5) and 
Cordiol (TC-7). These compounds induced significant 
increase in phagocytic activity by activation of the 
peritoneal macrophages (Kapil A. and Sharma S., 
1997). It is important to recall here that macrophages 
play an important role in nonspecific and specific 
immune responses. In innate immunity, the 
phagocytosis of foreign bodies by macrophages and 
other phagocytes contributes to regulation of both 
humoral and cellular immune responses.[32] 
Macrophages are the second line of defense and 
constitute important participants in the bi-directional 
interaction between innate and specific immunity. 
Macrophages are in a quiescent form and are 
activated when given a stimulus. Enhanced secretion 
of lysozyme by macrophage cell line J774A on 
treatment with Tinospora cordifolia and 
lipopolysaccharide was observed, suggesting activated 
state of macrophages. Enhanced lysozyme production 
was reported at  different time intervals (24 hrs and 
48 hrs.[33] 
Withania sominifera commonly known as 
Ashwagandha contain pharmacologically active 
compounds Withanolide, which is basically steroid 
lactone and various types have been isolated from 
plant. In the Indian System of Medicine, Withania 
somnifera finds application for numerous ailments 
including inflammation. The plant also reported to 
have antistress, antioxidant, immunomodulatory, 
hemopoietic, and rejuvenating properties. 
Antiinflammatory activity was seen in methanolic 
fractions of Withania aerial parts, comparable to 
hydrocortisone; probably the activity was attributed 
to presence of biologically active steroids in the plant, 
of which withaferin A is known to be a major 
component 
The standardized root extract of Withania somnifera 
find useful applications against the intracellular 
pathogens and in the management of immune 
suppressed diseases. Immunomodulatory activity of 
Withania somnifera was studied and found that it 
prevented myelosuppression and significantly 
increased the hemoglobin concentration. RBC, WBC 
count, platelet count and body weight in mice. 
Administration of an extract from the powdered root 
of the plant Withania somnifera was found to 
stimulate immunological activity in mice. Treatment 
with five doses of Withania root extract was found to 
enhance the total WBC count on the 10th day. Bone 
marrow cellularity (27×106 cells/femur) as well as α-
esterase positive cell number (1800/4000 cells) also 
increased significantly  after the administration of 
Withania extract. Treatment with Withania extract 
along with the antigen (SRBC) produced an 
enhancement in the circulating antibody titre and the 
number of plaque forming cells (PFC) in the spleen. 
Maximum number of PFC (985 PFC/106 spleen cells) 
was obtained on the fourth day. Administration of 
Withania extract also showed an enhancement in 
phagocytic activity of peritoneal macrophages  when 
compared to control  in mice. These results confirm 
the immunomodulatory activity of Withania 
somnifera extract, which is a known immune 
modulator in indigenous medicine.[34] 
Ocimum sanctum has ability to modulate humoral 
immune responses by acting at various levels in 
immune mechanism such as antibody production; 
release of mediators of hypersensitivity reactions and 
tissue responses to these mediators in the target 
organs.[35] Methanol extract and aqueous suspension 
of Ocimum sanctum leaves have ability to stimulate 
humoral response.[36] Ocimum sanctum seed oil also 
has been proved to modulate both humoral and cell 
mediated responsiveness in both non-stressed and 
stressed experimental animals and mechanism behind 
these immunomodulatory properties could be due to 
their activity on GABAergic pathways.[37]  
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Glycyrrhetinic acid is isolated from Glycyrrhiza glabra. 
Glycyrrhetinic acid reported to show a promising anti-
inflammatory action, inhibit the release of histamine, 
serotonin, and bradykinin and lowers vascular 
permeability. It is also reported to inhibit formalin-
induced edema formation, granuloma weight and 
exudate amount. It has been reported that 
glycyrrhetinic acid produces protection against lung 
inflammatory diseases by producing anti-
inflammatory chemokines, IL-8 and eotaxin 1 from 
lung fibroblasts, by which neutrophils and eosinophils 
are strongly attracted during inflammation. 
Glycyrrhetinic acid acts similar to cortisone and useful 
for all sorts of inflammation. It has an anti-
inflammatory or allergic action by the suppression of 
PAF production. Glycyrrhetinic acid has a reputation 
as an excellent expectorant in the case of lung 
congestion and pharmacological studies indicate that 
it has sodium-retention, antidiuretic and anti-
inflammatory actions. It accelerates lymphocytic 
transformation activation of macrophage and 
increases the leucocyte count.[38,39] 
 A controlled clinical study with  combination of four 
important Rasayana drugs viz. Guduci (T.Cordifolia), 
Ashwagandha (W.Somnifera), Amalaki (Emblica 
officinalis) and Tulasi (Ocimum sanctum) in equal 
amounts was found to potentiate both the cellular 
and humoral components of immunity (Chatterjee S. 
& Das S.N., 1996). It significantly increased the 
microbicidal activity of the neutrophils and circulating 
levels of globulins and other components. It also 
significantly elevated the number of lymphocytes 
along with improvement in T-cell memory. The 
macrophage function study showed a significant 
increase in cell size, number of cells and phagocytic 
activity of macrophages with the administration of 
this combination. Chemotactic assay for phagocytic 
cells indicated positive chemo taxis for leukocytes.  
The combination was found to potentiate the immune 
status and helped in faster recovery when used as an 
adjunct to specific therapy in cancer, chronic wasting 
diseases, multidrug resistant tuberculosis and other 
immunocompromised conditions.[40,41] 
Analysis of the Indian government’s Ayurvedic 
immunity - boosting measures for the COVID-19 crisis 
has been done in a study and following possible mode 
of action has been proposed.[42] 
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Drink herbal tea made 
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black pepper, ginger, 
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and stress controlled 
trials 
Seen as a 
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coconut oil or ghee 
(clarified butter) twice 
a day 
 Seen as healing 
substance and a 
coolant for the 
body 
CONCLUSION 
As the various pathological organisms invading the 
human body has to come across defense mechanisms 
of our body. Our first line of defense consists of innate 
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immune system. It consists of skin, mucus membrane, 
macrophages and natural killer cells and different 
proteins and enzymes.[43] Alveolar macrophages, a 
type of white blood cells on the surface of alveoli are 
another defense mechanism for lungs. Because of the 
requirement of gas exchange alveoli are not protected 
by mucus and cilia. Mucus is too thick and would slow 
down movement of oxygen and CO2. Instead alveolar 
macrophages seek out deposited particles, bind to 
them, ingest them, kill microorganisms and digest 
them.[43] Hence our immune system has a very 
important role in the prevention of  disease 
progression. If the immune system becomes  weaker, 
the host will not be able to produce enough 
macrophages and hence more susceptible to 
infections. Some Ayurvedic drugs promote immunity 
through various mechanisms as proved by some of 
the recent researches. As the cases of novel 
coronavirus is increasing with a very wide range in 
severity of clinical symptoms. Corona virus disease 
(COVID-19) is an infectious disease caused by a newly 
discovered coronavirus. Most people infected with 
the COVID-19 virus will experience mild to moderate 
respiratory illness and recover without requiring 
special treatment.  Older people, and those with 
underlying medical problems like cardiovascular 
disease, diabetes, chronic respiratory disease, and 
cancer are more likely to develop serious illness. As 
people with these diseases have less efficient immune 
system as compared to healthy individuals this 
imposes that our immune system plays a key role in 
progression of diseases. So  Ayurvedic measures can 
be used to reduce the burden of severity of disease on 
our society. 
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